TEPSIN

Across TCGA pan-cancer cohorts, TEPSIN Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated TEPSIN data layer compared with 23 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TEPSIN Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TEPSIN expression acts as an unfavorable survival marker.

LUAD, COAD, and LUSC are the cancer types where TEPSIN Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.287	0.794	<.001	30	view →
COAD	OS	Median	II,III,IV	0.186	0.611	<.001	28	view →
LUSC	OS	Median	II,III,IV	0.046	0.737	<.001	24	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
UCEC	OS	Median	IV	0.225	0.772	<.001	12	view →
HNSC	OS	Median	All	0.182	0.661	.007	9	view →
TGCT	DFS	Median	All	0.094	0.801	.008	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
BLCA	DFS	Median	III,IV	0.139	0.572	.047	3	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

TEPSIN–LUAD (DFS)

Open the LUAD breakdown →